NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Portfolio Pulse from Benzinga Newsdesk
NeuroMetrix, Inc. (NASDAQ:NURO) announced that over 2000 fibromyalgia patients have been prescribed its Quell Fibromyalgia device since its launch in December 2022. The device, a TENS unit for fibromyalgia symptom reduction, has received positive feedback from healthcare providers. It is prescription-only, in line with FDA regulations, and can be used during sleep.
March 13, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroMetrix's Quell Fibromyalgia device has been prescribed to over 2000 patients, indicating a positive market reception and potential revenue growth.
The announcement of over 2000 prescriptions for Quell Fibromyalgia since its recent launch suggests a strong market demand and acceptance among healthcare providers. This early success could lead to increased revenue for NeuroMetrix and potentially boost investor confidence in the company's growth prospects. The positive testimonials from healthcare professionals further support the product's market viability and effectiveness, which could drive further adoption and sales.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100